138,600 Shares in Mesoblast Limited (NASDAQ:MESO) Acquired by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC purchased a new position in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 138,600 shares of the company's stock, valued at approximately $2,744,000. Strategic Financial Concepts LLC owned 0.12% of Mesoblast as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Mesoblast in the fourth quarter worth about $30,000. Signaturefd LLC boosted its position in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company's stock worth $45,000 after purchasing an additional 3,099 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock worth $133,000 after purchasing an additional 1,213 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Mesoblast during the 4th quarter valued at approximately $134,000. Finally, Creative Planning purchased a new position in shares of Mesoblast during the 3rd quarter valued at approximately $147,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Stock Down 1.8 %

NASDAQ:MESO traded down $0.31 during trading hours on Friday, reaching $16.92. 54,501 shares of the company were exchanged, compared to its average volume of 369,791. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. Mesoblast Limited has a twelve month low of $1.91 and a twelve month high of $22.00. The stock's 50-day moving average is $17.73 and its 200-day moving average is $11.69.

Wall Street Analyst Weigh In

MESO has been the topic of several analyst reports. Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a research report on Thursday, January 30th. Piper Sandler reissued an "overweight" rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Finally, Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.